Chinook Stock Analysis

KDNY -  USA Stock  

USD 12.57  0.47  3.88%

The current slide in stock price may raise some interest from investors. The stock closed today at a share price of 12.57 on 29,392 in trading volume. The company management teams have failed to build on market volatilities in July. However, diversifying your overall positions with Chinook Therapeutics may protect your principal portfolio during upcoming market swings. The stock standard deviation of daily returns for 90 days investing horizon is currently 3.78. The above-average risk is mostly attributed to market volatility and speculations regarding some of the upcoming earning calls from Chinook Therapeutics partners.
Please see Stocks Correlation.

Search Stock Analysis 

 
Refresh
The Chinook Therapeutics stock analysis report makes it easy to digest most publicly released information about Chinook Therapeutics and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Chinook Stock analysis module also helps to analyze the Chinook Therapeutics price relationship with some important fundamental indicators such as market cap and management efficiency.

Chinook Stock Analysis Notes

About 71.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 1.85. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Chinook Therapeutics recorded a loss per share of 5.01. The entity had not issued any dividends in recent years. The firm had 1-5 split on the 2nd of October 2020. Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. Its product candidates also include BION-1301, an anti-APRIL monoclonal antibody is being evaluated in a Phase Ib trial for IgA nephropathy and CHK-336, an oral small molecule LDHA inhibitor for the treatment of primary hyperoxaluria, as well as research programs for other rare and severe chronic kidney diseases. Chinook Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 105 people. To find out more about Chinook Therapeutics contact the company at 206 485 7051 or learn more at http://www.chinooktx.com.

Chinook Therapeutics Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Chinook Therapeutics' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Chinook Therapeutics or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Chinook Therapeutics generates negative expected return over the last 90 days
Chinook Therapeutics has high historical volatility and very poor performance
The company reported the previous year's revenue of 1.18 M. Net Loss for the year was (113.69 M) with loss before overhead, payroll, taxes, and interest of (33.47 M).
Chinook Therapeutics currently holds about 219.57 M in cash with (80.44 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.92.
Roughly 71.0% of the company shares are owned by institutional investors
Latest headline from MacroaxisInsider: Acquisition by Glicklich Alan of 21311 shares of Chinook Therapeutics subject to Rule 16b-3

Chinook Market Capitalization

The company currently falls under 'Small-Cap' category with current market capitalization of 539.86 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Chinook Therapeutics's market, we take the total number of its shares issued and multiply it by Chinook Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Management Efficiency

The entity has return on total asset (ROA) of (22.59) % which means that it has lost $22.59 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (76.26) %, meaning that it created substantial loss on money invested by shareholders. Chinook Therapeutics management efficiency ratios could be used to measure how well chinook therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.

Technical Drivers

As of the 5th of August, Chinook Therapeutics shows the mean deviation of 2.39, and Risk Adjusted Performance of (0.09). Chinook Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to interpolate nineteen technical drivers for Chinook Therapeutics, which can be compared to its rivals. Please confirm Chinook Therapeutics downside deviation, treynor ratio, as well as the relationship between the Treynor Ratio and expected short fall to decide if Chinook Therapeutics is priced correctly, providing market reflects its regular price of 12.57 per share. Given that Chinook Therapeutics has jensen alpha of (0.46), we suggest you to validate Chinook Therapeutics's prevailing market performance to make sure the company can sustain itself at a future point.

Chinook Therapeutics Price Movement Analysis

The output start index for this execution was twenty-nine with a total number of output elements of thirty-two. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Chinook Therapeutics middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Chinook Therapeutics. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target. View also all equity analysis or get more info about bollinger bands overlap studies indicator.

Chinook Therapeutics Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Chinook Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Chinook Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Chinook Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Glicklich Alan over two weeks ago via Macroaxis 
Acquisition by Glicklich Alan of 21311 shares of Chinook Therapeutics subject to Rule 16b-3
Dobmeier Eric over a month ago via Macroaxis 
Exercise or conversion by Dobmeier Eric of 20000 shares of Chinook Therapeutics subject to Rule 16b-3
Frohlich Tom over a month ago via Macroaxis 
Acquisition by Frohlich Tom of 30000 shares of Chinook Therapeutics subject to Rule 16b-3
Akkaraju Srinivas over a month ago via Macroaxis 
Acquisition by Akkaraju Srinivas of 5948 shares of Chinook Therapeutics subject to Rule 16b-3
Thomas Dolca over a month ago via Macroaxis 
Acquisition by Thomas Dolca of 5948 shares of Chinook Therapeutics subject to Rule 16b-3
Dobmeier Eric over two months ago via Macroaxis 
Purchase by Dobmeier Eric of 1000 shares of Chinook Therapeutics
Frohlich Tom over three months ago via Macroaxis 
Acquisition by Frohlich Tom of 20406 shares of Chinook Therapeutics subject to Rule 16b-3
Dobmeier Eric over six months ago via Macroaxis 
Exercise or conversion by Dobmeier Eric of 20000 shares of Chinook Therapeutics subject to Rule 16b-3
Bjerkholt Eric over six months ago via Macroaxis 
Acquisition by Bjerkholt Eric of 49243 shares of Chinook Therapeutics subject to Rule 16b-3
Dobmeier Eric over six months ago via Macroaxis 
Purchase by Dobmeier Eric of 2000 shares of Chinook Therapeutics
Dobmeier Eric over six months ago via Macroaxis 
Purchase by Dobmeier Eric of 929 shares of Chinook Therapeutics
Bjerkholt Eric over six months ago via Macroaxis 
Chinook Therapeutics exotic insider transaction detected

Chinook Therapeutics Predictive Daily Indicators

Chinook Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Chinook Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Chinook Therapeutics Forecast Models

Chinook Therapeutics time-series forecasting models is one of many Chinook Therapeutics' stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Chinook Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

About Chinook Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Chinook Therapeutics stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Chinook shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as Chinook Therapeutics. By using and applying Chinook Stock analysis, traders can create a robust methodology for identifying Chinook entry and exit points for their positions.
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. Its product candidates also include BION-1301, an anti-APRIL monoclonal antibody is being evaluated in a Phase Ib trial for IgA nephropathy and CHK-336, an oral small molecule LDHA inhibitor for the treatment of primary hyperoxaluria, as well as research programs for other rare and severe chronic kidney diseases. Chinook Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 105 people.

Be your own money manager

As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding Chinook Therapeutics to your portfolios without increasing risk or reducing expected return.

Did you try this?

Run Stock Screener Now

   

Stock Screener

Find equities using custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
All  Next Launch Module
Please see Stocks Correlation. Note that the Chinook Therapeutics information on this page should be used as a complementary analysis to other Chinook Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.

Complementary Tools for Chinook Stock analysis

When running Chinook Therapeutics price analysis, check to measure Chinook Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Chinook Therapeutics is operating at the current time. Most of Chinook Therapeutics' value examination focuses on studying past and present price action to predict the probability of Chinook Therapeutics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Chinook Therapeutics' price. Additionally, you may evaluate how the addition of Chinook Therapeutics to your portfolios can decrease your overall portfolio volatility.
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Go
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Go
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Go
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Go
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Go
CEO Directory
Screen CEOs from public companies around the world
Go
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Go
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Go
The market value of Chinook Therapeutics is measured differently than its book value, which is the value of Chinook that is recorded on the company's balance sheet. Investors also form their own opinion of Chinook Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Chinook Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Chinook Therapeutics' market value can be influenced by many factors that don't directly affect Chinook Therapeutics underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Chinook Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine Chinook Therapeutics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Chinook Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.